Atorvastatin cost
Searched over 200M research papers for "atorvastatin cost"
Summary
10 papers analyzed
These studies suggest atorvastatin is a cost-effective treatment for the primary prevention of cardiovascular disease, particularly in patients with type 2 diabetes and those at moderate to high risk, with benefits often outweighing the costs.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
Cost-Effectiveness of Atorvastatin: An Overview
Introduction to Atorvastatin Cost-Effectiveness
Atorvastatin, a lipid-lowering agent, has been extensively studied for its cost-effectiveness in preventing cardiovascular events, particularly in patients with type 2 diabetes and those with a history of cardiovascular disease. This article synthesizes findings from multiple studies to provide a comprehensive overview of the cost-effectiveness of atorvastatin.
Cost-Effectiveness in Type 2 Diabetes
Primary Prevention in Type 2 Diabetes
Several studies have evaluated the cost-effectiveness of atorvastatin in the primary prevention of cardiovascular disease in patients with type 2 diabetes. The Collaborative Atorvastatin Diabetes Study (CARDS) demonstrated that atorvastatin 10 mg daily is a cost-effective intervention. The incremental cost-effectiveness ratio (ICER) was estimated to be £7,608 per year free of any CARDS primary endpoint, £4,896 per year free of any cardiovascular endpoint, and £4,120 per year free of any study endpoint over the trial period. Over a patient's lifetime, the cost per quality-adjusted life-year (QALY) was £6,471, which falls within the acceptable threshold specified by the National Institute for Health and Clinical Excellence (NICE).
Economic Analysis in Different Regions
The cost-effectiveness of atorvastatin has also been analyzed in various regions. In France, the ICER was estimated to be €3,862 per clinical event avoided over the trial period, and €1,418 per year when considering all-cause death over a patient's lifetime. In Canada, the incremental cost-effectiveness of atorvastatin was $70,773 per QALY at 5 years, $12,687 per QALY at 10 years, and $1,362 per QALY at 25 years, indicating increasing cost-effectiveness over time.
Cost-Effectiveness in Cardiovascular Disease Prevention
ASCOT-LLA Trial
The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-LLA) assessed the cost-effectiveness of atorvastatin in patients with hypertension and no history of coronary heart disease. The ICERs were €12,673 in Sweden and €11,693 in the UK per event avoided, suggesting that atorvastatin is a cost-effective strategy in these populations.
SPARCL Trial
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial evaluated the economic implications of atorvastatin in patients with a recent stroke or transient ischemic attack. The study found that atorvastatin provided health benefits at an acceptable cost, with an ICER of $13,916 per QALY gained.
High-Dose Atorvastatin
IDEAL Trial
The Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial compared high-dose atorvastatin (80 mg/day) with standard-dose simvastatin (20-40 mg/day) in patients with a history of myocardial infarction. The ICER for high-dose atorvastatin was $26,795 per QALY gained, which remained below the commonly used cost-effectiveness threshold in 78% of simulations.
Acute Coronary Syndromes
In patients with acute coronary syndromes, high-dose atorvastatin was found to be cost-effective compared to standard-dose statins. The study projected cost savings and a favorable ICER, particularly if the cost of atorvastatin decreases following patent expiration.
Conclusion
Atorvastatin has demonstrated significant cost-effectiveness in various populations, particularly in the primary prevention of cardiovascular events in patients with type 2 diabetes and in secondary prevention in patients with a history of cardiovascular disease. The ICERs across different studies and regions consistently fall within acceptable thresholds, making atorvastatin a valuable intervention from both a clinical and economic perspective.
Sources and full results
Most relevant research papers on this topic
